Clinical study on the interrelationship between liver, heart, and lung in portal hypertension

Clinical study on the interrelationship between liver, heart, and lung in portal hypertension - The interrelationship between liver, heart, and lung in portal hypertension

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042876

Enrollment

100

Registered

2021-01-04

Start date

2021-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Portal hypertension

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients scheduled for treatment of complications associated with portal hypertension (splenomegaly, portal hypertension, esophagogastric varices, refractory ascites) or patients suspected of having cirrhotic cardiomyopathy or portopulmonary hypertension due to respiratory distress, etc. 2) Age 20 years or older 3) Patients who have received sufficient explanation about the study after receiving sufficient explanation about their medical conditions and treatment methods, and who have obtained written consent of their own free will with sufficient understanding.

Exclusion criteria

Exclusion criteria: (1) Patients whom the principal investigator or sub-investigator judges to be inappropriate as subjects. (2) Patients for whom outpatient follow-up at our hospital is difficult.

Design outcomes

Primary

Measure	Time frame
Frequency of cirrhotic cardiomyopathy and portopulmonary hypertension in patients with portal Hypertension and at 3 months and 1 year	—

Secondary

Measure	Time frame
a. Examine the relationship between liver reserve values (blood chemistry, Child-Pugh score, MELD score, and liver elasticity) and cardiac and portopulmonary hypertension factors. b. Examine the relationship between portal hemodynamic severity (hepatic venous pressure gradient, Doppler flow factors in portal vein and portosystemic shunt) and cardiac function factors and pulmonary hypertension factors. c. To examine changes in cardiac function and pulmonary hypertension factors after treatment of complications associated with portal hypertension. d. Examine the relationship of prognosis to cardiac function and pulmonary hypertension factors. e. Examine differences in endothelin, cytokines, and BMP9 by angiographic site and changes after treatment.	—

Measure

Time frame

a. Examine the relationship between liver reserve values (blood chemistry, Child-Pugh score, MELD score, and liver elasticity) and cardiac and portopulmonary hypertension factors. b. Examine the relationship between portal hemodynamic severity (hepatic venous pressure gradient, Doppler flow factors in portal vein and portosystemic shunt) and cardiac function factors and pulmonary hypertension factors. c. To examine changes in cardiac function and pulmonary hypertension factors after treatment of complications associated with portal hypertension. d. Examine the relationship of prognosis to cardiac function and pulmonary hypertension factors. e. Examine differences in endothelin, cytokines, and BMP9 by angiographic site and changes after treatment.

—

Countries

Japan

Contacts

Public ContactHidemi Unozawa

Chiba University Hospital Department of Gastroenterology

unozawa.hidemi@chiba-u.jp0432227171

Outcome results